Literature DB >> 21517041

Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

Robert Y Zhao1, Sharon D Wilhelm, Charlene Audette, Gregory Jones, Barbara A Leece, Alexandru C Lazar, Victor S Goldmacher, Rajeeva Singh, Yelena Kovtun, Wayne C Widdison, John M Lambert, Ravi V J Chari.   

Abstract

The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody-maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21517041     DOI: 10.1021/jm2002958

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

Review 1.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

Review 2.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

3.  Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

Authors:  Robert P Lyon; Tim D Bovee; Svetlana O Doronina; Patrick J Burke; Joshua H Hunter; Haley D Neff-LaFord; Mechthild Jonas; Martha E Anderson; Jocelyn R Setter; Peter D Senter
Journal:  Nat Biotechnol       Date:  2015-06-15       Impact factor: 54.908

Review 4.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

Review 5.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

6.  Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Authors:  L Nathan Tumey; Fengping Li; Brian Rago; Xiaogang Han; Frank Loganzo; Sylvia Musto; Edmund I Graziani; Sujiet Puthenveetil; Jeffrey Casavant; Kimberly Marquette; Tracey Clark; Jack Bikker; Eric M Bennett; Frank Barletta; Nicole Piche-Nicholas; Amy Tam; Christopher J O'Donnell; Hans Peter Gerber; Lioudmila Tchistiakova
Journal:  AAPS J       Date:  2017-04-24       Impact factor: 4.009

7.  Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Authors:  Leanna R Staben; Stefan G Koenig; Sophie M Lehar; Richard Vandlen; Donglu Zhang; Josefa Chuh; Shang-Fan Yu; Carl Ng; Jun Guo; Yanzhou Liu; Aimee Fourie-O'Donohue; MaryAnn Go; Xin Linghu; Nathaniel L Segraves; Tao Wang; Jinhua Chen; BinQing Wei; Gail D Lewis Phillips; Keyang Xu; Katherine R Kozak; Sanjeev Mariathasan; John A Flygare; Thomas H Pillow
Journal:  Nat Chem       Date:  2016-10-17       Impact factor: 24.427

8.  Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron-Nitrogen Heterocycle.

Authors:  Tak Ian Chio; Han Gu; Kamalika Mukherjee; L Nathan Tumey; Susan L Bane
Journal:  Bioconjug Chem       Date:  2019-05-03       Impact factor: 4.774

9.  The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.

Authors:  Renpeng Liu; Xuan Chen; Junia Dushime; Megan Bogalhas; Alexandru C Lazar; Thomas Ryll; Lintao Wang
Journal:  MAbs       Date:  2017-01-31       Impact factor: 5.857

Review 10.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.